These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 22419147)

  • 1. A screening study of drug-drug interactions in cerivastatin users: an adverse effect of clopidogrel.
    Floyd JS; Kaspera R; Marciante KD; Weiss NS; Heckbert SR; Lumley T; Wiggins KL; Tamraz B; Kwok PY; Totah RA; Psaty BM
    Clin Pharmacol Ther; 2012 May; 91(5):896-904. PubMed ID: 22419147
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Glucuronidation converts clopidogrel to a strong time-dependent inhibitor of CYP2C8: a phase II metabolite as a perpetrator of drug-drug interactions.
    Tornio A; Filppula AM; Kailari O; Neuvonen M; Nyrönen TH; Tapaninen T; Neuvonen PJ; Niemi M; Backman JT
    Clin Pharmacol Ther; 2014 Oct; 96(4):498-507. PubMed ID: 24971633
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cerivastatin, genetic variants, and the risk of rhabdomyolysis.
    Marciante KD; Durda JP; Heckbert SR; Lumley T; Rice K; McKnight B; Totah RA; Tamraz B; Kroetz DL; Fukushima H; Kaspera R; Bis JC; Glazer NL; Li G; Austin TR; Taylor KD; Rotter JI; Jaquish CE; Kwok PY; Tracy RP; Psaty BM
    Pharmacogenet Genomics; 2011 May; 21(5):280-8. PubMed ID: 21386754
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lack of adverse clopidogrel-atorvastatin clinical interaction from secondary analysis of a randomized, placebo-controlled clopidogrel trial.
    Saw J; Steinhubl SR; Berger PB; Kereiakes DJ; Serebruany VL; Brennan D; Topol EJ;
    Circulation; 2003 Aug; 108(8):921-4. PubMed ID: 12925453
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Potential for conflict of interest in the evaluation of suspected adverse drug reactions: use of cerivastatin and risk of rhabdomyolysis.
    Psaty BM; Furberg CD; Ray WA; Weiss NS
    JAMA; 2004 Dec; 292(21):2622-31. PubMed ID: 15572720
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A frameshift variant of CYP2C8 was identified in a patient who suffered from rhabdomyolysis after administration of cerivastatin.
    Ishikawa C; Ozaki H; Nakajima T; Ishii T; Kanai S; Anjo S; Shirai K; Inoue I
    J Hum Genet; 2004; 49(10):582-585. PubMed ID: 15365880
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clearance rates of cerivastatin metabolites in a patient with cerivastatin-induced rhabdomyolysis.
    Ozaki H; Ishikawa CT; Ishii T; Toyoda A; Murano T; Miyashita Y; Shirai K
    J Clin Pharm Ther; 2005 Apr; 30(2):189-92. PubMed ID: 15811174
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cerivastatin in vitro metabolism by CYP2C8 variants found in patients experiencing rhabdomyolysis.
    Kaspera R; Naraharisetti SB; Tamraz B; Sahele T; Cheesman MJ; Kwok PY; Marciante K; Heckbert SR; Psaty BM; Totah RA
    Pharmacogenet Genomics; 2010 Oct; 20(10):619-29. PubMed ID: 20739906
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Interaction of statins with clopidogrel].
    Von Scheidt W
    Internist (Berl); 2004 Mar; 45(3):363-5. PubMed ID: 14997315
    [No Abstract]   [Full Text] [Related]  

  • 10. Estimating the extent of reporting to FDA: a case study of statin-associated rhabdomyolysis.
    McAdams M; Staffa J; Dal Pan G
    Pharmacoepidemiol Drug Saf; 2008 Mar; 17(3):229-39. PubMed ID: 18175291
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Thienopyridines and statins: assessing a potential drug-drug interaction.
    Neubauer H; Mügge A
    Curr Pharm Des; 2006; 12(10):1271-80. PubMed ID: 16611111
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High-dose atorvastatin on the pharmacodynamic effects of double-dose clopidogrel in patients undergoing percutaneous coronary interventions: The ACHIDO (Atorvastatin and Clopidogrel HIgh DOse in stable patients with residual high platelet activity) study.
    Leoncini M; Toso A; Maioli M; Angiolillo DJ; Giusti B; Marcucci R; Abbate R; Bellandi F
    JACC Cardiovasc Interv; 2013 Feb; 6(2):169-79. PubMed ID: 23428009
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Epidemiology of CYP3A4-mediated clopidogrel drug-drug interactions and their clinical consequences.
    Tirkkonen T; Heikkilä P; Vahlberg T; Huupponen R; Laine K
    Cardiovasc Ther; 2013 Dec; 31(6):344-51. PubMed ID: 23773422
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of clopidogrel on the steady-state pharmacokinetics of fluvastatin.
    Ayalasomayajula SP; Vaidyanathan S; Kemp C; Prasad P; Balch A; Dole WP
    J Clin Pharmacol; 2007 May; 47(5):613-9. PubMed ID: 17442686
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Withdrawal of cerivastatin revealed a flaw of post-marketing surveillance system in the United States].
    Saito M; Hirata-Koizumi M; Miyake S; Hasegawa R
    Kokuritsu Iyakuhin Shokuhin Eisei Kenkyusho Hokoku; 2005; (123):41-5. PubMed ID: 16541751
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Thienopyridine-associated drug-drug interactions: pharmacologic mechanisms and clinical relevance.
    Hulot JS; Collet JP; Montalescot G
    Curr Cardiol Rep; 2011 Oct; 13(5):451-8. PubMed ID: 21826477
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of drug interactions on biotransformation and antiplatelet effect of clopidogrel in vitro.
    Zahno A; Brecht K; Bodmer M; Bur D; Tsakiris DA; Krähenbühl S
    Br J Pharmacol; 2010 Sep; 161(2):393-404. PubMed ID: 20735423
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Concomitant use of clopidogrel and statins and risk of major adverse cardiovascular events following coronary stent implantation.
    Schmidt M; Johansen MB; Maeng M; Kaltoft A; Jensen LO; Tilsted HH; Bøtker HE; Baron JA; Sørensen HT
    Br J Clin Pharmacol; 2012 Jul; 74(1):161-70. PubMed ID: 22243420
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Individual pharmacotherapy safety in the assessment of cytochrome P-450 3A4 (CYP3A4) isoenzyme activity].
    Sivkov AS; Paukov SV; Ruvinov IuV; Kukes IV
    Klin Med (Mosk); 2010; 88(2):61-7. PubMed ID: 21105476
    [TBL] [Abstract][Full Text] [Related]  

  • 20. OATP1B1-related drug-drug and drug-gene interactions as potential risk factors for cerivastatin-induced rhabdomyolysis.
    Tamraz B; Fukushima H; Wolfe AR; Kaspera R; Totah RA; Floyd JS; Ma B; Chu C; Marciante KD; Heckbert SR; Psaty BM; Kroetz DL; Kwok PY
    Pharmacogenet Genomics; 2013 Jul; 23(7):355-64. PubMed ID: 23652407
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.